Glück Conviction Score™ ⓘ
LYEL
Lyell Immunopharma, Inc.
ⓘ
Eingeschränkte Aussagekraft — erst 66 % der Signal-Gewichte sind mit Daten unterlegt.
Effektiv: Neutral
Niedrig
Bedeutung der Einstufung ⓘ
Insider
0,0
Keine Insider-Käufe
Institutionell
36,9
17 neu, 24 erhöht, -38423K $ netto
Aktivist
26,1
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,69% (Stand: 31.05.2026)
Score-Verlauf (90 Tage)
Farbzonen = Stärkestufen (Sehr schwach … Sehr stark). Exit-Score unter der Schwelle = Timing-Ausstieg. Komponenten per Legende einblenden.
Kursverlauf (12 Monate)
Technische Indikatoren
Technical-Score basiert auf 12 Indikatoren (Trend, Momentum, Volatilität, Position) mit fixen Gewichten — wird aktuell nur informativ angezeigt und fließt nicht in den Glück Conviction Score ein. Integration nach Backtest-Kalibrierung (P5).
| Indikator | Signal | Gewicht | Wert | Detail | Beitrag |
|---|---|---|---|---|---|
| Kurs vs SMA50 | Bärisch | 10 % | 19.23 | -29.8 % vs SMA50 | |
| Kurs vs SMA200 | Bärisch | 15 % | 20.74 | -34.9 % vs SMA200 | |
| SMA-Cross | Bärisch | 10 % | DEATH | vor 10 Tagen @ 17.33 | |
| EMA20 vs EMA50 | Bärisch | 5 % | 15.19 | EMA50: 17.95 | |
| MACD-Histogramm | Bärisch | 10 % | -0.017 | Bearisch | |
| RSI(14) | Neutral | 10 % | 35.4 | Neutral (30–70) | |
| Stoch %K(14) | Neutral | 5 % | 30.3 | Neutral | |
| ADX(14)+DI | Bärisch | 10 % | 42.2 | +DI: 15.1 / −DI: 26.9 | |
| Z-Score(60) | Bullisch | 5 % | -1.68 | Extrem überverkauft | |
| 52W-Position | Bärisch | 5 % | 16.1 % | Hoch 38.60 / Tief 8.69 | |
| Bollinger(20,2σ) | Neutral | 5 % | 28.7 % | Upper 19.34 / Mid 15.24 / Lower 11.15 | |
| LinReg-Slope(60) | Bärisch | 10 % | -0.1502 | R²=0.56 / annualisiert -195.7 % |
Insider-Transaktionen (12 Monate) ⓘ
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-06-10 | Shook David | Officer, Chief Medical Officer | Open Market Sale | -1.977 | 12,64 | -24.989,28 | -2,7% | |
| 2026-03-06 | ARCH Venture Partners IX, LLC | 10% Owner | Open Market Purchase | 488.090 | 25,61 | 12.499.984,90 | +1371,9% | |
| 2026-03-06 | ARCH Venture Fund XIII, L.P. | 10% Owner | Open Market Purchase | 488.090 | 25,61 | 12.499.984,90 | +1371,9% | |
| 2026-02-11 | Seely Lynn | Director, Officer, President and CEO | Open Market Sale | -7.455 | 23,39 | -174.372,45 | -19,1% | |
| 2026-02-11 | Lee Gary K. | Officer, Chief Scientific Officer | Open Market Sale | -1.671 | 23,39 | -39.084,69 | -4,3% | |
| 2026-02-11 | Hill Stephen J. | Officer, Chief Operating Officer | Open Market Sale | -1.236 | 23,39 | -28.910,04 | -3,2% | |
| 2026-02-10 | Seely Lynn | Director, Officer, President and CEO | Open Market Sale | -438 | 23,12 | -10.126,56 | -1,1% | |
| 2026-02-10 | Lee Gary K. | Officer, Chief Scientific Officer | Open Market Sale | -147 | 23,12 | -3.398,64 | -0,4% | |
| 2026-02-10 | Hill Stephen J. | Officer, Chief Operating Officer | Open Market Sale | -109 | 23,12 | -2.520,08 | -0,3% | |
| 2026-02-10 | Bulis Veronica Sanchez | Officer, VP, Corporate Controller | Open Market Sale | -254 | 23,12 | -5.872,48 | -0,6% | |
| 2025-12-30 | Bulis Veronica Sanchez | Officer, VP, Corporate Controller | Open Market Sale | -936 | 32,32 | -30.251,52 | -3,3% | |
| 2025-12-24 | Bulis Veronica Sanchez | Officer, VP, Corporate Controller | Open Market Sale | -1.136 | 38,67 | -43.929,12 | -4,8% | |
| 2025-11-10 | Lee Gary K. | Officer, Chief Scientific Officer | Open Market Sale | -138 | 16,16 | -2.230,08 | -0,2% | |
| 2025-11-10 | Bulis Veronica Sanchez | Officer, VP, Corporate Controller | Open Market Sale | -239 | 16,10 | -3.847,90 | -0,4% | |
| 2025-11-10 | Hill Stephen J. | Officer, Chief Operating Officer | Open Market Sale | -95 | 16,12 | -1.531,40 | -0,2% | |
| 2025-11-10 | Seely Lynn | Director, Officer, President and CEO | Open Market Sale | -412 | 16,11 | -6.637,32 | -0,7% | |
| 2025-08-21 | Hill Stephen J. | Officer, Chief Operating Officer | Open Market Sale | -1.004 | 10,54 | -10.586,18 | -1,2% | |
| 2025-08-21 | Newton Charles W. | Officer, Chief Financial Officer | Open Market Sale | -1.453 | 10,54 | -15.320,43 | -1,7% | |
| 2025-08-21 | Seely Lynn | Director, Officer, President and CEO | Open Market Sale | -7.257 | 10,54 | -76.517,81 | -8,4% | |
| 2025-08-21 | Lee Gary K. | Officer, Chief Scientific Officer | Open Market Sale | -1.453 | 10,54 | -15.320,43 | -1,7% | |
| 2025-08-12 | Lee Gary K. | Officer, Chief Scientific Officer | Open Market Sale | -136 | 10,34 | -1.405,97 | -0,2% | |
| 2025-08-12 | Newton Charles W. | Officer, Chief Financial Officer | Open Market Sale | -136 | 10,34 | -1.405,97 | -0,2% | |
| 2025-08-12 | Hill Stephen J. | Officer, Chief Operating Officer | Open Market Sale | -94 | 10,34 | -971,77 | -0,1% | |
| 2025-08-12 | Seely Lynn | Director, Officer, President and CEO | Open Market Sale | -406 | 10,34 | -4.197,23 | -0,5% | |
| 2025-08-11 | Hill Stephen J. | Officer, Chief Operating Officer | Open Market Sale | -91 | 10,53 | -957,87 | -0,1% | |
| 2025-08-11 | Seely Lynn | Director, Officer, President and CEO | Open Market Sale | -391 | 10,53 | -4.115,67 | -0,5% | |
| 2025-08-11 | Lee Gary K. | Officer, Chief Scientific Officer | Open Market Sale | -131 | 10,53 | -1.378,91 | -0,2% | |
| 2025-08-11 | Newton Charles W. | Officer, Chief Financial Officer | Open Market Sale | -131 | 10,53 | -1.378,91 | -0,2% |
Fondsaktivität (Vorquartalsvergleich) ⓘ
| Fonds | Aktuell (Stk) | Vorquartal (Stk) | Veränderung (Stk) | Wert (USD) | Status | Δ | Trend |
|---|---|---|---|---|---|---|---|
| ARCH Venture Management, LLC | 3.247.162 | 0 | 3.247.162 | 65.138.070 | Neu | +100,0% | |
| MWG Caph Ltd | 1.008.116 | 0 | 1.008.116 | 31.029.810 | Neu | +100,0% | |
| GSK plc | 1.512.659 | 1.512.659 | 0 | 30.343.940 | Unverändert | 0,0% | |
| VANGUARD GROUP INC | 826.430 | 0 | 826.430 | 25.437.516 | Neu | +100,0% | |
| Foresite Capital Management IV, LLC | 800.399 | 800.399 | 0 | 16.056.004 | Unverändert | 0,0% | |
| Orland Properties Ltd | 754.698 | 754.698 | 0 | 15.139.242 | Unverändert | 0,0% | |
| VANGUARD CAPITAL MANAGEMENT LLC | 718.155 | 0 | 718.155 | 14.406.189 | Neu | +100,0% | |
| Decheng Capital LLC | 692.050 | 692.050 | 0 | 13.882.523 | Unverändert | 0,0% | |
| Almitas Capital LLC | 577.807 | 577.807 | 0 | 11.590.808 | Unverändert | 0,0% | |
| Foresite Capital Management V, LLC | 477.078 | 477.078 | 0 | 9.570.185 | Unverändert | 0,0% | |
| MILLENNIUM MANAGEMENT LLC | 458.905 | 58.651 | 400.254 | 9.205.634 | Aufgestockt | +682,4% | |
| CITADEL ADVISORS LLC | 393.462 | 340.701 | 52.761 | 7.892.848 | Aufgestockt | +15,5% | |
| venBio Partners LLC | 337.697 | 337.697 | 0 | 6.774.202 | Unverändert | 0,0% | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 310.198 | 159.416 | 150.782 | 6.222.572 | Aufgestockt | +94,6% | |
| Alphabet Inc. | 293.256 | 293.256 | 0 | 5.882.715 | Unverändert | 0,0% | |
| BlackRock, Inc. | 191.820 | 181.837 | 9.983 | 3.847.910 | Aufgestockt | +5,5% | |
| GEODE CAPITAL MANAGEMENT, LLC | 166.980 | 162.997 | 3.983 | 3.351.556 | Aufgestockt | +2,4% | |
| Invesco Ltd. | 98.649 | 0 | 98.649 | 3.036.416 | Neu | +100,0% | |
| MARSHALL WACE, LLP | 148.516 | 73.315 | 75.201 | 2.979.230 | Aufgestockt | +102,6% | |
| RENAISSANCE TECHNOLOGIES LLC | 116.411 | 39.490 | 76.921 | 2.335.205 | Aufgestockt | +194,8% | |
| GOLDMAN SACHS GROUP INC | 114.491 | 96.675 | 17.816 | 2.296.689 | Aufgestockt | +18,4% | |
| Velan Capital Investment Management LP | 102.000 | 0 | 102.000 | 2.046.120 | Neu | +100,0% | |
| MIC Capital Management UK LLP | 87.028 | 87.028 | 0 | 1.745.782 | Unverändert | 0,0% | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 85.971 | 85.423 | 548 | 1.724.578 | Aufgestockt | +0,6% | |
| JOHNSON & JOHNSON | 54.887 | 0 | 54.887 | 1.689.422 | Neu | +100,0% | |
| Opaleye Management Inc. | 79.097 | 0 | 79.097 | 1.586.686 | Neu | +100,0% | |
| STATE STREET CORP | 72.522 | 51.472 | 21.050 | 1.454.791 | Aufgestockt | +40,9% | |
| JANE STREET GROUP, LLC | 63.893 | 12.409 | 51.484 | 1.281.694 | Aufgestockt | +414,9% | |
| MORGAN STANLEY | 56.151 | 42.949 | 13.202 | 1.126.389 | Aufgestockt | +30,7% | |
| Qube Research & Technologies Ltd | 55.110 | 9.051 | 46.059 | 1.105.507 | Aufgestockt | +508,9% | |
| DIMENSIONAL FUND ADVISORS LP | 47.888 | 0 | 47.888 | 958.999 | Neu | +100,0% | |
| RBF Capital, LLC | 44.094 | 74.585 | -30.491 | 884.526 | Reduziert | -40,9% | |
| Ikarian Capital, LLC | 41.081 | 41.081 | 0 | 824.084 | Unverändert | 0,0% | |
| Clearstead Advisors, LLC | 39.916 | 0 | 39.916 | 800.715 | Neu | +100,0% | |
| BANK OF AMERICA CORP /DE/ | 33.321 | 8.045 | 25.276 | 668.420 | Aufgestockt | +314,2% | |
| UBS Group AG | 31.814 | 13.203 | 18.611 | 638.188 | Aufgestockt | +141,0% | |
| Clarius Group, LLC | 19.958 | 0 | 19.958 | 614.307 | Neu | +100,0% | |
| NORTHERN TRUST CORP | 30.280 | 30.280 | 0 | 607.417 | Unverändert | 0,0% | |
| CANADA PENSION PLAN INVESTMENT BOARD | 29.411 | 32.111 | -2.700 | 589.985 | Reduziert | -8,4% | |
| Walleye Capital LLC | 22.207 | 0 | 22.207 | 445.472 | Neu | +100,0% | |
| Point72 Asset Management, L.P. | 21.292 | 11.480 | 9.812 | 427.118 | Aufgestockt | +85,5% | |
| Susquehanna Portfolio Strategies, LLC | 20.800 | 20.800 | 0 | 417.248 | Unverändert | 0,0% | |
| Jump Financial, LLC | 20.123 | 0 | 20.123 | 403.667 | Neu | +100,0% | |
| Squarepoint Ops LLC | 19.294 | 0 | 19.294 | 387.038 | Neu | +100,0% | |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 18.000 | 18.000 | 0 | 361.080 | Unverändert | 0,0% | |
| AMERICAN CENTURY COMPANIES INC | 15.971 | 0 | 15.971 | 320.378 | Neu | +100,0% | |
| BOOTHBAY FUND MANAGEMENT, LLC | 9.516 | 0 | 9.516 | 292.902 | Neu | +100,0% | |
| Brevan Howard Capital Management LP | 13.435 | 0 | 13.435 | 269.506 | Neu | +100,0% | |
| ExodusPoint Capital Management, LP | 8.511 | 0 | 8.511 | 261.969 | Neu | +100,0% | |
| RAYMOND JAMES FINANCIAL INC | 7.900 | 0 | 7.900 | 243.162 | Neu | +100,0% |
Top-Fondshalter (Stand: 31.03.2026) ⓘ
| Fonds | Anteile | Vorquartal (Stk) | Δ | Wert (USD) | Anteil (%) |
|---|---|---|---|---|---|
| ARCH Venture Management, LLC | 3.247.162 | 0 | +100,0% | 65.138.070 | 26,16 |
| GSK plc | 1.512.659 | 1.512.659 | 0,0% | 30.343.940 | 12,19 |
| Foresite Capital Management IV, LLC | 800.399 | 800.399 | 0,0% | 16.056.004 | 6,45 |
| Orland Properties Ltd | 754.698 | 754.698 | 0,0% | 15.139.242 | 6,08 |
| VANGUARD CAPITAL MANAGEMENT LLC | 718.155 | 0 | +100,0% | 14.406.189 | 5,79 |
| Decheng Capital LLC | 692.050 | 692.050 | 0,0% | 13.882.523 | 5,58 |
| Almitas Capital LLC | 577.807 | 577.807 | 0,0% | 11.590.808 | 4,66 |
| Foresite Capital Management V, LLC | 477.078 | 477.078 | 0,0% | 9.570.185 | 3,84 |
| MILLENNIUM MANAGEMENT LLC | 458.905 | 58.651 | +682,4% | 9.205.634 | 3,70 |
| CITADEL ADVISORS LLC | 393.462 | 340.701 | +15,5% | 7.892.848 | 3,17 |
| venBio Partners LLC | 337.697 | 337.697 | 0,0% | 6.774.202 | 2,72 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 310.198 | 159.416 | +94,6% | 6.222.572 | 2,50 |
| Alphabet Inc. | 293.256 | 293.256 | 0,0% | 5.882.715 | 2,36 |
| BlackRock, Inc. | 191.820 | 181.837 | +5,5% | 3.847.910 | 1,55 |
| GEODE CAPITAL MANAGEMENT, LLC | 166.980 | 162.997 | +2,4% | 3.351.556 | 1,35 |
| MARSHALL WACE, LLP | 148.516 | 73.315 | +102,6% | 2.979.230 | 1,20 |
| RENAISSANCE TECHNOLOGIES LLC | 116.411 | 39.490 | +194,8% | 2.335.205 | 0,94 |
| GOLDMAN SACHS GROUP INC | 114.491 | 96.675 | +18,4% | 2.296.689 | 0,92 |
| Velan Capital Investment Management LP | 102.000 | 0 | +100,0% | 2.046.120 | 0,82 |
| MIC Capital Management UK LLP | 87.028 | 87.028 | 0,0% | 1.745.782 | 0,70 |
Halter-Trend (6 Quartale)
| Periode | Status | Halter | Anteile (Mio) | Wert (Mio $) |
|---|---|---|---|---|
| 31.03.2026 | ✓ | 76 | 13,5 | 267 |
| 31.12.2025 | ✓ | 70 | 9,6 | 296 |
| 30.09.2025 | ✓ | 59 | 8,5 | 131 |
| 30.06.2025 | ✓ | 71 | 9,3 | 79 |
| 31.03.2025 | ✓ | 109 | 154,9 | 79 |
| 31.12.2024 | ✓ | 102 | 151,8 | 92 |
Top 10 Neueinsteiger
| Fonds | Anteile | Wert (USD) ⓘ |
|---|---|---|
| GSK plc | 1.512.659 | 46.559.644 |
| MWG Caph Ltd | 1.008.116 | 31.029.810 |
| Invesco Ltd. | 98.649 | 3.036.416 |
| GOLDMAN SACHS GROUP INC | 96.675 | 2.975.657 |
| MARSHALL WACE, LLP | 73.315 | 2.256.635 |
| JANE STREET GROUP, LLC | 12.409 | 381.949 |
| Point72 Asset Management, L.P. | 11.480 | 353.354 |
| Qube Research & Technologies Ltd | 9.051 | 278.590 |
| ExodusPoint Capital Management, LP | 8.511 | 261.969 |
| RAYMOND JAMES FINANCIAL INC | 7.900 | 243.162 |
Top 10 Aufstocker
| Fonds | Anteile | Δ Anteile ⓘ | Δ % ⓘ | Wert (USD) ⓘ |
|---|---|---|---|---|
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 159.416 | 143.257 | +886.5 % | 4.906.824 |
| Decheng Capital LLC | 692.050 | 96.584 | +16.2 % | 21.301.299 |
| VANGUARD GROUP INC | 826.430 | 47.426 | +6.1 % | 25.437.516 |
| GEODE CAPITAL MANAGEMENT, LLC | 162.997 | 32.740 | +25.1 % | 5.019.879 |
| STATE STREET CORP | 51.472 | 17.720 | +52.5 % | 1.584.308 |
| BARCLAYS PLC | 15.967 | 14.775 | +1239.5 % | 491.465 |
| MORGAN STANLEY | 42.949 | 5.929 | +16.0 % | 1.321.971 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 85.423 | 5.913 | +7.4 % | 2.629.320 |
| BlackRock, Inc. | 181.837 | 5.031 | +2.8 % | 5.596.944 |
| BANK OF AMERICA CORP /DE/ | 8.045 | 3.366 | +71.9 % | 247.625 |
Top 10 Verkäufer
| Fonds | Anteile | Δ Anteile ⓘ | Δ % ⓘ | Wert (USD) ⓘ |
|---|---|---|---|---|
| venBio Partners LLC | 337.697 | -135.782 | -28.7 % | 10.394.314 |
| MILLENNIUM MANAGEMENT LLC | 58.651 | -66.710 | -53.2 % | 1.805.278 |
| RENAISSANCE TECHNOLOGIES LLC | 39.490 | -24.500 | -38.3 % | 1.215.502 |
| RBF Capital, LLC | 74.585 | -21.046 | -22.0 % | 2.295.726 |
| CITADEL ADVISORS LLC | 340.701 | -15.540 | -4.4 % | 10.486.777 |
| ACADIAN ASSET MANAGEMENT LLC | 1.657 | -9.733 | -85.5 % | 51 |
| UBS Group AG | 13.203 | -8.039 | -37.8 % | 406.388 |
| TWO SIGMA INVESTMENTS, LP | 15.616 | -5.211 | -25.0 % | 480.660 |
| ROYAL BANK OF CANADA | 24 | -4.163 | -99.4 % | 1.000 |
| Ikarian Capital, LLC | 41.081 | -2.718 | -6.2 % | 1.264.473 |
Aktivisten & Großaktionäre (13D/13G) ⓘ
| Datum | Investor | Typ | Anteil | Aktien | Δ | Zweck |
|---|---|---|---|---|---|---|
| 15.05.2026 | Clinton Bybee | Passiv (13G/A) | 7,80 % | 1.820.634 | -0,80 pp | |
| 15.05.2026 | Keith Crandell | Passiv (13G/A) | 13,90 % | 3.247.162 | +0,90 pp | |
| 15.05.2026 | ARCH Venture Partners IX Overage, L.P. | Passiv (13G/A) | 13,90 % | 3.247.162 | +0,90 pp | |
| 15.05.2026 | Kristina Burow | Passiv (13G/A) | 13,90 % | 3.247.162 | +0,90 pp | |
| 15.05.2026 | ARCH Venture Partners IX, L.P. | Passiv (13G/A) | 13,90 % | 3.247.162 | +0,90 pp | |
| 15.05.2026 | ARCH Venture Fund XIII, L.P. | Passiv (13G/A) | 13,90 % | 3.247.162 | +0,90 pp | |
| 15.05.2026 | Paul Berns | Passiv (13G/A) | 6,10 % | 1.426.528 | +1,70 pp | |
| 15.05.2026 | ARCH Venture Fund IX Overage, L.P. | Passiv (13G/A) | 13,90 % | 3.247.162 | +0,90 pp | |
| 15.05.2026 | ARCH Venture Fund IX, L.P. | Passiv (13G/A) | 13,90 % | 3.247.162 | +0,90 pp | |
| 15.05.2026 | Robert Nelsen | Passiv (13G/A) | 13,90 % | 3.247.162 | +0,90 pp | |
| 15.05.2026 | ARCH Venture Partners XIII, LLC | Passiv (13G/A) | 13,90 % | 3.247.162 | +0,90 pp | |
| 15.05.2026 | Steven Gillis | Passiv (13G/A) | 13,90 % | 3.247.162 | +0,90 pp | |
| 15.05.2026 | ARCH Venture Partners IX, LLC | Passiv (13G/A) | 13,90 % | 3.247.162 | +0,90 pp | |
| 15.05.2026 | ARCH Venture Partners XIII, L.P. | Passiv (13G/A) | 13,90 % | 3.247.162 | +0,90 pp | |
| 11.05.2026 | MWG Caph Ltd | Passiv (13G/A) | 4,30 % | 1.008.116 | Neu | |
| 11.05.2026 | Milky Way Investments Group Ltd. | Passiv (13G/A) | 4,30 % | 1.008.116 | Neu | |
| 08.05.2026 | Explore Investments LLC | Passiv (13G/A) | 6,60 % | 1.529.054 | +1,20 pp | |
| 08.05.2026 | Jeffrey P. Bezos | Passiv (13G/A) | 6,60 % | 1.529.054 | +1,20 pp | |
| 21.04.2026 | EULER FUND, L.P. | Passiv (13G) | 6,71 % | 1.426.528 | Neu | |
| 21.04.2026 | Euler Managers Limited | Passiv (13G) | 6,71 % | 1.426.528 | Neu | |
| 21.04.2026 | Antonis Indianos | Passiv (13G) | 6,71 % | 1.426.528 | Neu | |
| 14.11.2025 | Foresite Capital Management IV, LLC | Passiv (13G/A) | 4,20 % | 800.339 | -1,20 pp | |
| 14.11.2025 | Foresite Capital Fund V, L.P. | Passiv (13G/A) | 2,50 % | 477.078 | -0,30 pp | |
| 14.11.2025 | Foresite Capital Opportunity Fund V, L.P. | Passiv (13G/A) | 0,90 % | 177.199 | -0,10 pp | |
| 14.11.2025 | Foresite Capital Opportunity Management V, LLC | Passiv (13G/A) | 0,90 % | 177.199 | -0,10 pp | |
| 14.11.2025 | James B. Tananbaum | Passiv (13G/A) | 7,60 % | 1.454.616 | -1,60 pp | |
| 14.11.2025 | Foresite Capital Management V, LLC | Passiv (13G/A) | 2,50 % | 477.078 | -0,30 pp | |
| 14.11.2025 | Foresite Capital Fund IV, L.P. | Passiv (13G/A) | 4,20 % | 800.339 | -1,20 pp | |
| 14.11.2025 | ARCH Venture Partners XIII, L.P. | Passiv (13G/A) | 13,00 % | 2.759.072 | Neu | |
| 14.11.2025 | ARCH Venture Fund XIII, L.P. | Passiv (13G/A) | 13,00 % | 2.759.072 | Neu | |
| 14.11.2025 | ARCH Venture Partners XIII, LLC | Passiv (13G/A) | 13,00 % | 2.759.072 | Neu | |
| 14.11.2025 | Kristina Burow | Passiv (13G/A) | 13,00 % | 2.759.072 | Neu | |
| 14.11.2025 | ARCH Venture Partners IX Overage, L.P. | Passiv (13G/A) | 13,00 % | 2.759.072 | 0,00 pp | |
| 14.11.2025 | ARCH Venture Fund IX Overage, L.P. | Passiv (13G/A) | 13,00 % | 2.759.072 | 0,00 pp | |
| 14.11.2025 | Robert Nelsen | Passiv (13G/A) | 13,00 % | 2.759.072 | -0,10 pp | |
| 14.11.2025 | ARCH Venture Partners IX, L.P. | Passiv (13G/A) | 13,00 % | 2.759.072 | 0,00 pp | |
| 14.11.2025 | Keith Crandell | Passiv (13G/A) | 13,00 % | 2.759.072 | 0,00 pp | |
| 14.11.2025 | Clinton Bybee | Passiv (13G/A) | 8,60 % | 1.820.634 | -4,40 pp | |
| 14.11.2025 | ARCH Venture Partners IX, LLC | Passiv (13G/A) | 13,00 % | 2.759.072 | 0,00 pp | |
| 14.11.2025 | ARCH Venture Fund IX, L.P. | Passiv (13G/A) | 13,00 % | 2.759.072 | 0,00 pp |
Stammdaten
Lyell Immunopharma, Inc., ein T-Zell-Reprogrammierungs-Unternehmen, ist in der Entwicklung von T-Zell-Therapien für Patienten mit soliden Tumoren tätig. Das Unternehmen entwickelt Therapien unter Verwendung von Technologieplattformen, wie Gen-R, eine ex-vivo-Gentechnik-Reprogrammierungstechnologie zur Überwindung von T-Zell-Erschöpfung; und Epi-R, eine ex-vivo-epigenetische Reprogrammierungstechnologie zur Erzeugung einer Population von T-Zellen mit langfristiger Stammhaftigkeit. Die Pipeline umfasst LYL797, einen T-Zell-Produktkandidaten zur Behandlung von nicht-kleinzelligem Lungenkrebs und triple-negativem Brustkrebs; LYL845, der mehrere solide Tumoren anvisiert; und NY-ESO-1 für synoviales Sarkom und andere Indikationen bei soliden Tumoren. Das Unternehmen ist eine Forschungs- und Entwicklungs-Kooperations- und Lizenzvereinbarung mit GlaxoSmithKline für das NY-ESO-1-Programm eingegangen. Lyell Immunopharma, Inc. wurde 2018 gegründet und hat seinen Hauptsitz in South San Francisco, Kalifornien.
Unternehmen & Branche
| Name | Lyell Immunopharma, Inc. |
|---|---|
| Ticker | LYEL |
| CIK | 0001806952 |
| Boerse | Nasdaq |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | 55083R104 |
|---|---|
| ISIN | US55083R1041 |
| Typ | Common Stock |
| Marktkapitalisierung | 291,6 Mio. USD |
| Beta | -0,05 |
Bewertung
| KBV (P/B) | 1,17 vs. 40,41 (2021) ▼ |
|---|---|
| KUV (P/S) | 8.099,13 vs. 3.528,25 (2021) ▲ |
| FCF-Rendite | -51,7 % vs. -0,5 % (2021) ▼ |
Qualität & Bilanz
| Operative Marge | -748.344,4 % vs. -2.016,7 % (2021) ▼ |
|---|---|
| Nettomarge | -762.355,6 % vs. -2.349,5 % (2021) ▼ |
| ROIC | -91,7 % vs. -25,1 % (2021) ▼ |
Basis: SEC-XBRL-Jahresabschluss bis 31.12.2025, Multiples mit aktueller Marktkapitalisierung (trailing), Vergleich: GJ bis 2021. Kennzahlen erklärt →
Kennzahlen-Historie (5 Jahre) – Tabelle & Verlauf
| Kennzahl | 2021 | 2022 | 2023 | 2024 | 2025 | Verlauf |
|---|---|---|---|---|---|---|
| Bewertung | ||||||
| KBV (P/B) | 40,41 | 20,79 | 15,04 | 0,49 | 2,64 | |
| KUV (P/S) | 3.528,25 | 204,53 | 75.796,61 | 3.093,78 | 18.169,91 | |
| FCF-Rendite | -0,5 % | -1,1 % | -1,7 % | -86,3 % | -23,1 % | |
| Buyback-Rendite | 0,0 % | 0,0 % | – | – | – | |
| Qualität & Bilanz | ||||||
| Operative Marge | -2.016,7 % | -220,9 % | -190.006,2 % | -588.123,0 % | -748.344,4 % | |
| Nettomarge | -2.349,5 % | -216,2 % | -180.486,2 % | -562.285,2 % | -762.355,6 % | |
| ROIC | -25,1 % | -20,3 % | -32,7 % | -77,6 % | -91,7 % | |
Basis: SEC-XBRL-Jahresabschlüsse, Multiples je Geschäftsjahr mit Marktkapitalisierung zum Bilanzstichtag (point-in-time).
Externe Quelle:
SEC EDGAR »
Externe Links: Yahoo Finance » · OnVista »
Finanzkennzahlen (SEC XBRL) ⓘ
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2026-03-31 | 10-Q | 2.000 | -24.153.000 | -1,10 | 350.626.000 | 273.665.000 |
| 2025-12-31 | 10-K | 36.000 | -274.448.000 | -16,06 | 340.052.000 | 248.202.000 |
| 2025-09-30 | 10-Q | 15.000 | -38.846.000 | -2,13 | 407.965.000 | 329.121.000 |
| 2025-06-30 | 10-Q | 8.000 | -42.684.000 | -2,89 | 385.453.000 | 298.923.000 |
| 2025-03-31 | 10-Q | 7.000 | -52.195.000 | -0,18 | 429.798.000 | 336.521.000 |
| 2024-12-31 | 10-K | 61.000 | -342.994.000 | -1,31 | 490.859.000 | 382.824.000 |
| 2024-09-30 | 10-Q | 34.000 | -44.583.000 | -0,17 | 619.215.000 | 530.697.000 |
| 2024-06-30 | 10-Q | 13.000 | -45.809.000 | -0,18 | 654.142.000 | 566.501.000 |
| 2024-03-31 | 10-Q | 3.000 | -60.667.000 | -0,24 | 694.220.000 | 603.157.000 |
| 2023-12-31 | 10-K | 130.000 | -234.632.000 | -0,93 | 750.029.000 | 654.952.000 |
| 2023-09-30 | 10-Q | 25.000 | -50.853.000 | -0,20 | 794.989.000 | 697.573.000 |
| 2023-06-30 | 10-Q | 27.000 | -63.890.000 | -0,26 | 835.354.000 | 736.855.000 |
| 2023-03-31 | 10-Q | 65.000 | -66.959.000 | -0,27 | 880.450.000 | 783.826.000 |
| 2022-12-31 | 10-K | 84.683.000 | -183.118.000 | -0,74 | 937.561.000 | 833.252.000 |
| 2022-09-30 | 10-Q | 3.000 | -70.254.000 | -0,28 | 977.269.000 | 820.026.000 |
| 2022-06-30 | 10-Q | 35.741.000 | -36.323.000 | -0,15 | 1.021.674.000 | 868.042.000 |
| 2022-03-31 | 10-Q | 553.000 | -68.144.000 | -0,28 | 1.072.103.000 | 881.249.000 |
| 2021-12-31 | 10-K | 10.650.000 | -250.219.000 | -1,84 | 1.127.406.000 | 929.787.000 |
| 2021-09-30 | 10-Q | 2.755.000 | -48.875.000 | -0,20 | 1.198.334.000 | 986.474.000 |
| 2021-06-30 | 10-Q | 2.628.000 | -62.595.000 | -1,47 | 1.229.867.000 | 1.021.955.000 |
Umsatz nach Segmenten & Regionen ⓘ
Geschäftssegmente
| Segment | FY 2025 | FY 2024 | FY 2023 | FY 2022 | Anteil | Δ | Trend |
|---|---|---|---|---|---|---|---|
| Reportable Segment | 36.000 | 61.000 | 130.000 | 84,7 Mio. | 100,0 % | -41,0% |
Quartalsergebnisse (Earnings) ⓘ
| Quartal | Stichtag | Verkündet | Umsatz | EPS |
|---|---|---|---|---|
| Q1 2026 | 31.03.2026 | 06.05.2026 | 2.000 USD | -1,10 |
| Q3 2025 | 30.09.2025 | 12.11.2025 | 15.000 USD | -2,13 |
| Q2 2025 | 30.06.2025 | 12.08.2025 | 8.000 USD | -2,89 |
| Q1 2025 | 31.03.2025 | 06.05.2026 | 7.000 USD | -3,54 |
| Q3 2024 | 30.09.2024 | 12.11.2025 | 34.000 USD | -3,48 |
| Q2 2024 | 30.06.2024 | 12.08.2025 | 13.000 USD | -3,59 |
| Q1 2024 | 31.03.2024 | 13.05.2025 | 3.000 USD | -0,24 |
| Q3 2023 | 30.09.2023 | 07.11.2024 | 25.000 USD | -0,20 |
| Q2 2023 | 30.06.2023 | 07.08.2024 | 27.000 USD | -0,26 |
Einreichungs-Historie (10-K / 10-Q)
SEC-Einreichungs-Historie der Quartalsberichte (10-Q) und Jahresberichte
(10-K) der letzten sechs Jahre. Die Spalte „Verzögerung" zeigt die
Tage zwischen Berichtsstichtag und tatsächlicher Einreichung.
Suffix /A kennzeichnet nachträgliche Berichtigungen.
| Eingereicht | Form | Berichtsperiode | Verzögerung | |
|---|---|---|---|---|
| 06.05.2026 | 10-Q | 31.03.2026 | 36 Tage | SEC » |
| 12.03.2026 | 10-K | 31.12.2025 | 71 Tage | SEC » |
| 12.11.2025 | 10-Q | 30.09.2025 | 43 Tage | SEC » |
| 12.08.2025 | 10-Q | 30.06.2025 | 43 Tage | SEC » |
| 13.05.2025 | 10-Q | 31.03.2025 | 43 Tage | SEC » |
| 11.03.2025 | 10-K | 31.12.2024 | 70 Tage | SEC » |
| 07.11.2024 | 10-Q | 30.09.2024 | 38 Tage | SEC » |
| 07.08.2024 | 10-Q | 30.06.2024 | 38 Tage | SEC » |
| 06.05.2024 | 10-Q | 31.03.2024 | 36 Tage | SEC » |
| 28.02.2024 | 10-K | 31.12.2023 | 59 Tage | SEC » |
| 07.11.2023 | 10-Q | 30.09.2023 | 38 Tage | SEC » |
| 08.08.2023 | 10-Q | 30.06.2023 | 39 Tage | SEC » |
| 04.05.2023 | 10-Q | 31.03.2023 | 34 Tage | SEC » |
| 28.02.2023 | 10-K | 31.12.2022 | 59 Tage | SEC » |
| 08.11.2022 | 10-Q | 30.09.2022 | 39 Tage | SEC » |
| 04.08.2022 | 10-Q | 30.06.2022 | 35 Tage | SEC » |
| 10.05.2022 | 10-Q | 31.03.2022 | 40 Tage | SEC » |
| 29.03.2022 | 10-K | 31.12.2021 | 88 Tage | SEC » |
| 12.11.2021 | 10-Q | 30.09.2021 | 43 Tage | SEC » |
| 12.08.2021 | 10-Q | 30.06.2021 | 43 Tage | SEC » |